Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Blood (2024) 144 (Supplement 1): 585.

https://doi.org/10.1182/blood-2024-211449

Published: 2024

Journal Articles

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

Charlotte Pawlyn, Faith E Davies, Gordon Cook, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Catherine Olivier, Anna Hockaday, John R Jones, Martin F Kaiser, Matthew W. Jenner, Walter Martin Gregory, Ruth M de Tute, Roger G Owen, Mark Drayson, David A. Cairns, Gareth Morgan, Graham Jackson

Blood (2024) 144 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2024-205788

Published: 2024

Journal Articles

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Graham Jackson, Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, David A. Cairns, Gareth Morgan

Blood (2024) 144 (Supplement 1): 3375.

https://doi.org/10.1182/blood-2024-205871

Published: 2024

Journal Articles

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, Gareth Morgan, David A. Cairns, Graham Jackson

Blood (2024) 144 (Supplement 1): 771.

https://doi.org/10.1182/blood-2024-208255

Published: 2024

Journal Articles

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Andy Rawstron, Nichola Webster, Surita Dalal, Ruth M de Tute, Sue Bell, David Allan Cairns, Sean Girvan, Natasha Greatorex, Anna Hockaday, Sharon Jackson, David Phillips, David Stones, David Allsup, Adrian John Clifton Bloor, Anita Sarma, Abraham Mullasseril Varghese, Talha Munir, Peter Hillmen

Blood (2023) 142 (Supplement 1): 632.

https://doi.org/10.1182/blood-2023-187943

Published: 2023

Journal Articles

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Blood (2023) 142 (Supplement 1): 4637.

https://doi.org/10.1182/blood-2023-180527

Published: 2023

Journal Articles

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Blood (2023) 142 (Supplement 1): 631.

https://doi.org/10.1182/blood-2023-178298

Published: 2023

Journal Articles

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Blood (2023) 142 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2023-188597

Published: 2023

Journal Articles

Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD)

Gordon Cook, A J Ashcroft, Ethan R Senior, Catherine Olivier, Anna Hockaday, Jeanine Richards, James D. Cavenagh, John Snowden, Mark Drayson, Ruth M de Tute, Roger Owen, Kwee Yong, Mamta Garg, Kevin Boyd, Hamdi Sati, Sharon Gillson, Mark Cook, David Allan Cairns, Christopher Parrish

Blood (2023) 142 (Supplement 1): 783.

https://doi.org/10.1182/blood-2023-188532

Published: 2023

Journal Articles

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Blood (2022) 140 (Supplement 1): 231–233.

https://doi.org/10.1182/blood-2022-170463

Published: 2022

Journal Articles

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Blood (2022) 140 (Supplement 1): 1844–1846.

https://doi.org/10.1182/blood-2022-168842

Published: 2022

Journal Articles

Redefining nonmeasurable multiple myeloma using mass spectrometry

Hannah V. Giles, Mark A. Cook, Mark Trehane Drayson, Gordon Cook, Nicola Jane Wright, Simon John North, Stephen Harding, David A. Cairns, Anna Hockaday, Martin F. Kaiser, Paul Moss, Faith E. Davies, Gareth J. Morgan, Graham Jackson, Guy Pratt

Blood (2022) 139 (6): 946–950.

https://doi.org/10.1182/blood.2021013794

Published: 2022

Includes: Supplemental data

Journal Articles

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2021-152167

Published: 2021

Journal Articles

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Hannah Victoria Giles, Mark T Drayson, Nicola Wright, Gordon Cook, Faith E. Davies, Gareth J Morgan, Ruth M. de Tute, Roger G Owen, David Cairns, Anna Hockaday, Tom Menzies, Martin F. Kaiser, Charlotte Pawlyn, Graham Jackson, Guy Pratt

Blood (2021) 138 (Supplement 1): 820.

https://doi.org/10.1182/blood-2021-150479

Published: 2021

Journal Articles

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Blood (2021) 138 (Supplement 1): 642.

https://doi.org/10.1182/blood-2021-152319

Published: 2021

Journal Articles

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Andrea GS Pepper, PhD, Antonella Zucchetto, PhD, Kevin Norris, PhD, Erika Tissino, PhD, Jerry Polesel, Zarni Soe, David Allsup, Anna Hockaday, Pei Loo Ow, Peter Hillmen, MBChB, PhD, Andrew Rawstron, PhD, Daniel Catovsky, MD FRCP, Riccardo Bomben, PhD, Duncan M Baird, PhD, Christopher Fegan, Valter Gattei, MD, Chris Pepper, BSc, PhD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-141279

Published: 2020

Journal Articles

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Charlotte A. Bradbury, Zoe Craig, Gordon Cook, Charlotte Pawlyn, David A. Cairns, Anna Hockaday, Andrea Paterson, Matthew W. Jenner, John R. Jones, Mark T. Drayson, Roger G. Owen, Martin F. Kaiser, Walter M. Gregory, Faith E. Davies, J. Anthony Child, Gareth J. Morgan, Graham H. Jackson

Blood (2020) 136 (9): 1091–1104.

https://doi.org/10.1182/blood.2020005125

Published: 2020

Includes: Supplemental data

Journal Articles

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Gordon Cook, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD, Kwee Yong, PhD, Jamie Cavenagh, MD PhD, John A Snowden, MD, Mark T Drayson, Mamta Garg, David Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M De Tute, BSc,MSc, Roger G. Owen, Cathy Williams, Mark Cook, MBChB,PhD

Blood (2018) 132 (Supplement 1): 255.

https://doi.org/10.1182/blood-2018-99-112116

Published: 2018

Journal Articles

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Blood (2018) 132 (Supplement 1): 122.

https://doi.org/10.1182/blood-2018-99-111117

Published: 2018

Journal Articles

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Blood (2018) 132 (Supplement 1): 2000.

https://doi.org/10.1182/blood-2018-99-110149

Published: 2018

NARROW

IGHV Unmutated Status, Low Tumor Lysis Risk Disease and BRAF Mutated Status Are Predictors for Early MRD Responders Treated with MRD Defined Ibrutinib with Venetoclax: Report of the UK NCRI FLAIR Study

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Ibrutinib and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab for Patients in NCRI FLAIR Study with Previously Untreated CLL: Assessment of Mutational Landscape of Patients at Baseline and Prognostic Impact

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study

Molecular Analysis at Relapse of Patients Treated on the Ibrutinib and Rituximab Arm of the National Multi-Centre Phase III FLAIR Study in Previously Untreated CLL Patients

Ixazomib-Based Consolidation and Maintenance Prolongs Progression-Free Survival after Salvage Autologous Stem Cell Transplantation (sASCT): Results from Interim Analysis of UK-MRA Myeloma XII (ACCoRD)

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Risk-Adapted Therapy Directed According to Response (RADAR, UK-MRA Myeloma XV) - Comparing MRD-Guided Treatment Escalation and De-Escalation Strategies in Patients with Newly Diagnosed Myeloma Suitable for Stem Cell Transplantation

Redefining nonmeasurable multiple myeloma using mass spectrometry

Sudden or Cardiac Deaths on Ibrutinib-Based Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial

Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Ibrutinib Plus Rituximab Is Superior to FCR in Previously Untreated CLL: Results of the Phase III NCRI FLAIR Trial

Telomere Length and CD49d Cooperate with IGHV Gene Status As Predictors of Long-Term Progression-Free Survival in CLL Patients Treated with FCR-Based Regimens

Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Progression Free Survival below 12 Months Following Stem Cell Transplant Is a Hallmark of High-Risk Myeloma Which Is Associated with Inferior Overall Survival — Data from the Ukmrc Myeloma XI Trial

Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only